PIMA538525
FSHR Monoclonal Antibody (3D5G9), Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIMA538525-Each-of-1 | In Stock | ₹ 48,371.50 |
PIMA538525 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 48,371.50
GST (18%): ₹ 8,706.87
Total Price: ₹ 57,078.37
Antigen
FSHR
Classification
Monoclonal
Concentration
1 mg/mL
Formulation
PBS with 0.05% sodium azide
Gene Accession No.
P23945
Gene Symbols
FSHR
Immunogen
Purified recombinant fragment of human FSHR (aa: extra 18-366) expressed in E. Coli.
Quantity
100 μg
Primary or Secondary
Primary
Target Species
Human
Product Type
Antibody
Isotype
IgG1
Applications
Flow Cytometry, Western Blot
Clone
3D5G9
Conjugate
Unconjugated
Gene
FSHR
Gene Alias
follicle stimulating hormone receptor; follicle-stimulating hormone receptor; Follitropin receptor; FSH receptor; Fshr; FSH-R; FSHR1; FSHRO; LGR1; ODG1
Host Species
Mouse
Purification Method
Protein G
Regulatory Status
RUO
Gene ID (Entrez)
2492
Content And Storage
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Form
Liquid
Related Products
Description
- This antibody has been tested in indirect ELISA
- Follicle-Stimulating Hormone Receptor (FSHR) expression has been reported in ovary, uterus, and testis
- ESTs have been isolated from testis libraries
- G-protein Coupled Receptors (GPCRs) comprise one of the largest families of signaling molecules with more than a thousand members currently predicted to exist
- All GPCRs share a structural motif consisting of seven membrane-spanning helices, and exist in both active and inactive forms
- An array of activating ligands participate in the conformation of GPCRs which leads to signaling via G-proteins and downstream effectors
- Ongoing studies have also shown the vast series of reactions which participate in the negative regulation of GPCRs
- This turn-off activity has tremendous implications for the physiological action of the cell, and continues to drive pharmacological research for new drug candidates
- Two blockbuster drugs which have been developed as GPCR-targeted pharmaceuticals are Zyprexa (Eli Lilly) and Claritin (Schering-Plough) which have multi-billion dollar shares of the mental health and allergy markets, respectively.